Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases.
The last earnings update was 24 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Akero Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Akero Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Akero Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Akero Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Akero Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Akero Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Akero Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Akero Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Akero Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Akero Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Andrew Cheng, MD, PhD, serves as Director of Arbutus Biopharma Corporation since August 17, 2019. He served as Chief Medical Officer & Executive Vice President of Gilead Sciences, Inc., since March 2018 until September 7, 2018. Dr. Cheng serves as the President and Chief Executive Officer at Akero Therapeutics Inc. since September 10, 2018 and serves as its Director. Dr. Cheng served as an Executive Vice President of Clinical Research & Development Operations at Gilead Sciences Inc. since January 2015 until March 2018. Dr. Cheng served as an Executive Vice President of HIV Therapeutics and Development Operations at Gilead Sciences Inc. since January 28, 2015. Dr. Cheng served as Senior Vice President of HIV Therapeutics at Gilead Sciences, Inc. until January 28, 2015. He is responsible for leading the company’s Medical Affairs organization, as well as overseeing clinical development for the company’s programs in HIV/AIDS. Dr. Cheng served as Senior Vice President of Development Operations at Gilead Sciences Inc., since January 2009 until March 2018. Dr. Cheng is responsible for Gilead's biometrics, clinical operations, drug safety and public health, project and portfolio management and regulatory affairs activities. He joined Gilead in 1999 and served as Vice President, Clinical Research, overseeing clinical development activities for Gilead's development-stage programs in HIV/AIDS. He has been Director of Global Virus Network since January 2013. He has been Director of Syntimmune, Inc. since April 2018. Prior to joining Gilead, he trained in internal medicine at the University of California, Los Angeles. Dr. Cheng received his Medical Degree and PhD in Cellular and Molecular Biology from Columbia University College of Physicians and Surgeons and holds a B.A. in biology from the Johns Hopkins University.
Insufficient data for Andrew to compare compensation growth.
Andrew's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Akero Therapeutics management team is less than 2 years, this suggests a new team.
Co-Founder & Chief Scientific Officer
Executive VP & Chief Development Officer
EVP, CFO & Head of Corporate Development
VP of Finance & Controller
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Akero Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
Jane Pritchett Henderson
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.